HbA1c variability and long-term glycemic control are linked to peripheral neuropathy in patients with type 1 diabetes

M. V. Pinto1,2*, L. C. G. F. Rosa3, L. F. Pinto1, J. R. Dantas3, G. F. Salles4, L. Zajdenverg3, M. Rodacki3 and M. A. Lima1

Abstract
Background: HbA1c variability has been linked to retinopathy, renal disease and autonomic neuropathy in patients with type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2D). Although the same relationship has been demonstrated for diabetic peripheral neuropathy (DPN) in patients with T2D, data for T1D are still lacking.

Methods: Patients older than 17 years of age with ≥10 years of T1D duration and follow-up were included. All patients underwent nerve conduction studies and neurological examination. Laboratorial data was retrospectively extracted from chart review. Mean HbA1c (mHbA1c) over 10 years was calculated, as well as HbA1c variability estimated by standard deviation (HbA1c-SD) and coefficient of variation (HbA1c-CV).

Results: Fifty patients with T1D were included (30 females and 21 non-caucasians), with mean age and T1D duration of 25.6 ± 5.0 and 17.9 ± 6.1 years, respectively. The frequency of DPN was 24%. Higher mHbA1c (10.4 ± % vs 8.1 ± %; p < 0.001), HbA1c-SD (1.8 ± 0.8 vs 0.9 ± 0.4; p < 0.001), and HbA1c-CV (1.7 ± 0.8 vs 1.2 ± 1.1; p = 0.006) were observed in patients with DPN compared to others. SD-HbA1c and HbA1c-CV were associated with DPN, diagnosed by either clinical or NCS criteria, independent of mHbA1c, age and gender.

Conclusions: Not only long-term glycemic control, but also its variability is associated with DPN in patients with T1D. Larger studies are required to confirm this finding.

Keywords: Diabetic peripheral neuropathy, Type 1 diabetes, Long-term glycemic control

Introduction
Long-term glycemic control is a well-known risk factor for diabetic chronic complications [1], but there is recent evidence that glucose variability (GV) may also play a role in their development [2].

GV can be interpreted as intraday or interday glucose variation or long-term variation of HbA1c, which can be assessed by standard deviation (HbA1c-SD) and coefficient of variation (HbA1c-CV) [3]. Short-term GV measured through indices such as mean amplitude glucose excursions (MAGE) has been associated with microvascular complications in patients with type 2 diabetes (T2D), but their relationship is less clear for type 1 diabetes (T1D) [4, 5]. HbA1c variability has been linked to retinopathy, renal disease and autonomic neuropathy in patients with T1D and T2D [6–8]. Although the same relationship has been demonstrated for diabetic peripheral neuropathy (DPN) in patients with T2D [9], data for T1D are still lacking. Our aim was to investigate the
association between DPN and HbA1c-SD or HbA1c-CV in individuals with T1D.

**Methods**

In this cross-sectional study, patients from the Federal University of Rio de Janeiro’s Diabetes clinic older than 17 years of age with ≥10 years of T1D duration and follow-up were included. Ethics Committee approved the study and subjects signed an informed consent. Laboratory data was obtained through review of medical charts. HbA1c was evaluated with NGSP certified method HPLC with coefficient of variation <2% (Biorad USA). The results of all HbA1c measurements available were used to calculate the mean HbA1c (mHbA1c) and HbA1c variability over 10 years. HbA1c variability was estimated by HbA1c-SD (standard deviation of the mHbA1c) and HbA1c-CV (HbA1c-CV = mHbA1c − SD/ [0.1 × mHbA1c]).

Between 2014 and 2015, patients underwent neurological examination performed by a neurologist (L.F.P.) and nerve conduction studies (NCS) performed by an experienced neurophysiologist (M.V.P.). DPN was diagnosed by symptoms or signs associated with abnormalities on NCS in sural and an additional nerve (Toronto Diabetic Neuropathy Expert Group criteria) [10]. Motor NCS were performed on median, ulnar, peroneal and tibial nerves with determination of conduction velocity, amplitude, distal motor latency, and F-waves (except for peroneal). Sensory NCS were performed on median, ulnar, superficial peroneal and sural following standard techniques [11]. NCS were done on non-dominant upper extremity and right leg.

Neuropathy symptoms score (NSS) and neuropathy disability score (NDS) evaluations were performed in all patients. Explanation of both scores is provided elsewhere [12, 13]. Briefly, NSS is a score of neuropathic symptoms that varies from 0–9, and is subdivided as mild (score 3–4), moderate (5–6) and severe (7–9) symptoms. NDS is a score of neuropathic findings on examination that varies from 0–10, and is subdivided as mild (score 3–5), moderate (6–8) and severe (9–10) signs of neuropathy. The minimum acceptable criteria for a diagnosis of peripheral neuropathy are: moderate signs with or without symptoms, or mild signs with moderate symptoms.

We compared NSS/NDS criteria (NSS/NDS-PN) to symptoms and/or signs plus abnormal NCS. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of NSS/NDS-PN for diagnosis of DPN were calculated.

Statistical analysis was performed using IBM SPSS 23.0 STATISTICS. For continuous measurements, results were expressed as mean and SD. Chi-square and Fisher tests were used to test associations between qualitative variables. Mann Whitney was used for continuous and nominal variables. Multivariate logistic regression was used to assess independent associations between mHbA1c, HbA1c-SD or HbA1c-CV with DPN ascertained by clinical criteria (NSS/NDS), NCS and or both. Multivariate analyses were first adjusted for age and sex (Model 1) and then further adjusted for BMI, and for the presence of essential hypertension and of other microvascular complications (Model 2). The results were presented as odds ratios (ORs) with their 95% confidence intervals (CIs). To allow comparisons between mHbA1c and HbA1c variability in their strengths of association with DPN, ORs were standardized for increments of 1-SD in each HbA1c parameter. A 2-tailed probability value <0.05 was considered significant.

**Results**

Fifty patients with T1D were included (30 females and 21 non-caucasians), with mean age and T1D duration of 25.6±5.0 and 17.9±6.1 years, respectively. The mean number of HbA1c measurements/year and mean-HbA1c throughout follow-up were 2.5±1.1 and 8.7±1.7%. The majority (56%) of patients were using human insulin (NPH) as basal insulin while 40% used long-acting insulin analogs and 4% used continuous system of insulin infusion. For bolus injections, short-acting insulin analogues were used in 50% of the cases and regular insulin in the other half of patients. The frequency of DPN was 24% (12/50 patients). Sixteen patients fulfilled combined NSS/NDS criteria for peripheral neuropathy (NSS/NDS-PN), of which 11 were from the DPN group (Toronto criteria) and 5 from the non-DPN group. Mean NSS and NDS scores were higher in DPN than in non-DPN group (4.2±3.2 vs 0.6±1.8; p<0.001 and 7.2±2.0 vs 1.4±2.1; p<0.001 respectively). Sensitivity, specificity, PPV and NPV of NSS/NDS-PN for DPN were 91.7%, 86.8%, 68.8% and NPV 97.4%, respectively.

Higher mHbA1c (10.4±% vs 8.1±%; p<0.001), HbA1c-SD (1.8±0.8 vs 0.9±0.4; p<0.001), and HbA1c-CV (1.7±0.8 vs 1.2±1.1; p=0.006) were observed in patients with DPN compared to others. SD-HbA1c and CV-HbA1c were associated with DPN, diagnosed by either clinical or NCS criteria, independent of mHbA1c and other potential confounders (Table 1). Moreover, strengths of associations were higher for HbA1c variability than for mHbA1c, except for DPN diagnosed by NCS.

**Discussion**

This study demonstrates the association between DPN and long-term HbA1c variability in patients with T1D. GV can activate overproduction of oxygen reactive species, increase production of inflammatory cytokines, induce cell apoptosis and stimulate epigenetic changes
that might increase the risk of DPN [14]. Therefore, a modern approach for glycemic control should focus not only on HbA1c levels, but also on GV [15].

Virk et al. were the first to study the influence of HbA1c variability for development of DPN and cardiac autonomic neuropathy (CAN), in a group of young patients with long-standing T1D [16]. HbA1c variability was associated with CAN but not with DPN. Moreover, the classic association of DPN with CAN was not present. These results were unexpected but DPN was diagnosed only with quantitative sensory testing (QST) abnormalities in thermal or vibratory threshold [16]. QST was not included in either the definition criteria of distal symmetric polyneuropathy of American Academy of Neurology [17] or Toronto expert panel in DPN due to high variability in sensitivity and specificity and difficult standardization and reproducibility [10]. Therefore, those results may be related to the selection of DPN criteria. We used symptoms, signs and NCS abnormalities, making the diagnosis of DPN more accurate and robust. Recently, Su et al., with similar diagnostic criteria, showed that increased HbA1c variability is closely associated with DPN in patients with T2D [18].

Our study has limitations. We did not exclude patients with less than two HbA1c measurements per year. However, the mean number of HbA1c measurements was comparable to other longitudinal studies [19, 20]. We did not use a specific method to evaluate small sensory nerve fibers rather than neurological examination. In addition, short-term GV was not evaluated. Finally, the small sample size prevented more comprehensive statistical adjustments. Nonetheless, this was the first study to demonstrate the association of HbA1C variability over time and DPN in T1D patients.

Table 1 Results of multivariate logistic regression for the associations between HbA1c parameters (mean and variability) and presence of peripheral neuropathy by clinical and nerve conduction studies criteria

| HbA1c parameters | Diabetic peripheral neuropathy diagnosis |
|------------------|-----------------------------------------|
|                  | Clinical (NSS/NDS) n = 16               |
|                  | Nerve conduction studies n = 14         |
|                  | Clinical and NCS (Toronto criteria) n = 12 |
|                  | Model 1* OR (95% CI)                  |
|                  | Model 2* OR (95% CI)                  |
|                  | Model 1* OR (95% CI)                  |
|                  | Model 2* OR (95% CI)                  |
|                  | Model 1* OR (95% CI)                  |
|                  | Model 2* OR (95% CI)                  |
| HbA1c-SD         | 3.65 (1.11–12.05)†                    |
| Mean HbA1c       | 2.21 (0.84–5.81)‡                     |
| HbA1c-CV         | 2.75 (1.06–7.09)†                     |
| Mean HbA1c       | 3.26 (1.28–8.26)†                     |

NSS neuropathy symptoms score, NDS neuropathy disability score, NCS nerve conduction study, OR odds ratio, CI confidence interval

* Odds ratios were estimated for increments of 1 – SD in each HbA1c parameter (mean HbA1c 1.7%, HbA1c-SD 0.7% and HbA1c-CV 6.3), and adjusted for age and sex in Model 1 and further adjusted for BMI, presence of essential hypertension and of other microvascular complications in Model 2. †p < 0.05; ‡p < 0.01

**Conclusion**

Not only long-term glycemic control, but also its variability is associated with DPN in patients with T1D. Larger studies are required to confirm this finding.

**Abbreviations**

DPN: Diabetic peripheral neuropathy; GV: Glucose variability; mHbA1c: Mean HbA1c in the study period (2006–2015); NSS: Neuropathy symptom score; NDS: Neuropathy disability score; NSS/NDS-PN: Combined NSS/NDS criteria for peripheral neuropathy; HbA1c-SD: Standard deviation of all HbA1c measurements during the study period (2006–2015); HbA1c-VC: Variation coefficient of all HbA1c measurements during the study period (2006–2015); T1D: Type 1 diabetes mellitus; T2D: Type 2 diabetes mellitus.

**Acknowledgements**

No acknowledgements.

**Authors’ contributions**

MVP: Concept and design, acquisition of data, analysis and interpretations, drafting and revisions. JRD, LZ and MR: Concept and design, and critical revisions of manuscript. MAL: Concept and design, acquisition of data, drafting and critical revisions of manuscript and study supervision. All authors read and approved the final manuscript.

**Funding**

No funding.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Federal University of Rio de Janeiro Ethics Committee approved the study and subjects signed an informed consent.

**Consent for publication**

All authors attest to the validity and legitimacy of the data and its interpretation. All authors have read the final manuscript and agree to its submission.

**Competing interests**

Authors have no conflict of interest.

**Author details**

1 Neurology Section, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 2 Department of Neurology, Mayo Clinic, Rochester, MN, USA. 3 Nurology and Diabetes Section, Federal University of Rio de Janeiro, Rio de Janeiro.
References

1. The Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.

2. Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes Endocrinol. 2019;7(3):221–30.

3. Waden J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes. 2009;58(11):2649–55.

4. Smith-Palmer J, Brandle M, Trevisan R, Orsini Federici M, Liabat S, Valensine W. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(3):273–84.

5. Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, et al. Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial. Diabetes Care. 2017;40(6):777–83.

6. Rosa L, Zajdenverg L, Souto DL, Dantas JR, Pinto MVR, Salles G, et al. HbA1C variability and long-term glycaemic control are linked to diabetic retinopathy and glomerular filtration rate in patients with type 1 diabetes and multiethnic background. J Diabetes Complicat. 2019;33(9):610–5.

7. Lai YR, Huang CC, Chiu WC, Liu RT, Tsai NW, Wang HC, et al. HbA1C variability is strongly associated with the severity of cardiovascular autonomic neuropathy in patients with type 2 diabetes after longer diabetes duration. Front Neuosci. 2019;13:458.

8. Lee MY, Huang JC, Chen SC, Chiou HC, Wu PY. Association of HbA1C variability and renal progression in patients with type 2 diabetes with chronic kidney disease stages 3–4. Int J Mol Sci. 2018;19(12):4116.

9. Cardoso CRL, Leite NC, Moram CBM, Salles GF. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. Cardiovasc Diabetol. 2018;17(1):33.

10. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–93.

11. Kimura J. Normal values for nerve conduction studies. In: Kimura J, editor. Electrodiagnosis in diseases of nerve and muscle principles and practice. 4th ed. Oxford: Oxford University Press; 2013. p. 977–980.

12. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetes. Muscle Nerve. 1988;11(1):212–32.

13. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36(2):150–4.

14. Wentworth IM, Kulik W, Michels RP, Hoekstra JB, Devries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51(1):183–90.

15. Ceriello A, Genovese S, Bosi E. The evolving frontier of diabetes therapy: the renaissance of glycemology. Diabetes Res Clin Pract. 2016;118:168–71.

16. Vilk SA, Donagheue KC, Cha YH, Benitez-Aguirre P, Hing S, Pyke A, et al. Association between HbA1c variability and risk of microvascular complications in adolescents with type 1 diabetes. J Clin Endocrinol Metab. 2016;101(9):3257–63.

17. England JD, Groshet G, Franklin G, Miller RG, Asbury AK, Carter GT, et al. Distal symmetric polyneuropathy: a definition for clinical research report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64(2):199–207.

18. Su JB, Zhao LH, Zhang XL, Cai HL, Huang HY, Xu F, et al. HbA1C variability and diabetic peripheral neuropathy in type 2 diabetic patients. Cardiovasc Diabetol. 2018;17(1):47.

19. Lovestam-Adrian M, Agardh CD, Torffvit O, Agardh E. Diabetic retinopathy, visual acuity, and medical risk indicators: a continuous 10-year follow-up study in Type 1 diabetic patients under routine care. J Diabetes Complicat. 2001;15(6):287–94.

20. Nordwall M, Abrahamsson M, Dhir M, Fredrikson M, Ludvigsson J, Arnvist HJ. Impact of Hba1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes Care. 2015;38(2):308–15.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.